Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients (clinicaltrials.gov) - Apr 14, 2021 - P1; N=15; Completed; Sponsor: United BioPharma; Recruiting ➔ Completed
Trial completion • Chronic Spontaneous Urticaria • Dermatology • Urticaria
|